Cargando…
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study
OBJECTIVES: Due to a substantial proportion of asymptomatic and mild courses, many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed to determine and characterize the rate...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677041/ https://www.ncbi.nlm.nih.gov/pubmed/33221432 http://dx.doi.org/10.1016/j.cmi.2020.11.009 |
_version_ | 1783611899583135744 |
---|---|
author | Weis, Sebastian Scherag, André Baier, Michael Kiehntopf, Michael Kamradt, Thomas Kolanos, Steffi Ankert, Juliane Glöckner, Stefan Makarewicz, Oliwia Hagel, Stefan Bahrs, Christina Kimmig, Aurelia Proquitté, Hans Guerra, Joel Rimek, Dagmar Löffler, Bettina Pletz, Mathias W. |
author_facet | Weis, Sebastian Scherag, André Baier, Michael Kiehntopf, Michael Kamradt, Thomas Kolanos, Steffi Ankert, Juliane Glöckner, Stefan Makarewicz, Oliwia Hagel, Stefan Bahrs, Christina Kimmig, Aurelia Proquitté, Hans Guerra, Joel Rimek, Dagmar Löffler, Bettina Pletz, Mathias W. |
author_sort | Weis, Sebastian |
collection | PubMed |
description | OBJECTIVES: Due to a substantial proportion of asymptomatic and mild courses, many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed to determine and characterize the rate of SARS-CoV-2 infections and the resulting seroprevalence in a defined population. The primary objective of the study was to assess SARS-CoV-2 antibody seroprevalence using six different IgG-detecting immunoassays. Secondary objectives of the study were: (a) to determine potential risk factors for symptomatic versus asymptomatic coronavirus disease 2019 courses, and (b) to investigate the rate of virus RNA-persistence. METHODS: CoNAN is a population-based cohort study performed in the community Neustadt am Rennsteig, Germany, which was quarantined from 22 March to 5 April after six SARS-CoV-2 cases were detected in the village's population. The SARS-CoV-2 outbreak comprised 51 cases and 3 deaths. The CoNAN study was performed from 13 May to 22 May 2020, 6 weeks after a SARS-CoV-2 outbreak. RESULTS: We enrolled a total of 626 participants (71% of the community population) for PCR and antibody testing in the study. All actual SARS-CoV-2 PCR tests were negative. Fifty-two out of 620 (8.4%) participants had antibodies against SARS-CoV-2 in at least two different assays. There were 38 participants with previously PCR-confirmed SARS-CoV-2 infection. Of those, only 19 (50%) displayed anti-SARS-CoV-2 antibodies. We also show that antibody-positive participants with symptoms compatible with a respiratory tract infection had significantly higher antibody levels then asymptomatic participants (EU-assay: median 2.9 versus 7.2 IgG-index, p 0.002; DS-assay: median 45.2 versus 143 AU/mL, p 0.002). Persisting viral replication was not detected. CONCLUSIONS: Our data question the relevance and reliability of IgG antibody testing to detect past SARS-CoV-2 infections 6 weeks after an outbreak. We conclude that assessing immunity for SARS-CoV-2 infection should not rely on antibody tests alone. |
format | Online Article Text |
id | pubmed-7677041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76770412020-11-20 Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study Weis, Sebastian Scherag, André Baier, Michael Kiehntopf, Michael Kamradt, Thomas Kolanos, Steffi Ankert, Juliane Glöckner, Stefan Makarewicz, Oliwia Hagel, Stefan Bahrs, Christina Kimmig, Aurelia Proquitté, Hans Guerra, Joel Rimek, Dagmar Löffler, Bettina Pletz, Mathias W. Clin Microbiol Infect Original Article OBJECTIVES: Due to a substantial proportion of asymptomatic and mild courses, many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed to determine and characterize the rate of SARS-CoV-2 infections and the resulting seroprevalence in a defined population. The primary objective of the study was to assess SARS-CoV-2 antibody seroprevalence using six different IgG-detecting immunoassays. Secondary objectives of the study were: (a) to determine potential risk factors for symptomatic versus asymptomatic coronavirus disease 2019 courses, and (b) to investigate the rate of virus RNA-persistence. METHODS: CoNAN is a population-based cohort study performed in the community Neustadt am Rennsteig, Germany, which was quarantined from 22 March to 5 April after six SARS-CoV-2 cases were detected in the village's population. The SARS-CoV-2 outbreak comprised 51 cases and 3 deaths. The CoNAN study was performed from 13 May to 22 May 2020, 6 weeks after a SARS-CoV-2 outbreak. RESULTS: We enrolled a total of 626 participants (71% of the community population) for PCR and antibody testing in the study. All actual SARS-CoV-2 PCR tests were negative. Fifty-two out of 620 (8.4%) participants had antibodies against SARS-CoV-2 in at least two different assays. There were 38 participants with previously PCR-confirmed SARS-CoV-2 infection. Of those, only 19 (50%) displayed anti-SARS-CoV-2 antibodies. We also show that antibody-positive participants with symptoms compatible with a respiratory tract infection had significantly higher antibody levels then asymptomatic participants (EU-assay: median 2.9 versus 7.2 IgG-index, p 0.002; DS-assay: median 45.2 versus 143 AU/mL, p 0.002). Persisting viral replication was not detected. CONCLUSIONS: Our data question the relevance and reliability of IgG antibody testing to detect past SARS-CoV-2 infections 6 weeks after an outbreak. We conclude that assessing immunity for SARS-CoV-2 infection should not rely on antibody tests alone. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-03 2020-11-20 /pmc/articles/PMC7677041/ /pubmed/33221432 http://dx.doi.org/10.1016/j.cmi.2020.11.009 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Weis, Sebastian Scherag, André Baier, Michael Kiehntopf, Michael Kamradt, Thomas Kolanos, Steffi Ankert, Juliane Glöckner, Stefan Makarewicz, Oliwia Hagel, Stefan Bahrs, Christina Kimmig, Aurelia Proquitté, Hans Guerra, Joel Rimek, Dagmar Löffler, Bettina Pletz, Mathias W. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title | Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title_full | Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title_fullStr | Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title_full_unstemmed | Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title_short | Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study |
title_sort | antibody response using six different serological assays in a completely pcr-tested community after a coronavirus disease 2019 outbreak—the conan study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677041/ https://www.ncbi.nlm.nih.gov/pubmed/33221432 http://dx.doi.org/10.1016/j.cmi.2020.11.009 |
work_keys_str_mv | AT weissebastian antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT scheragandre antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT baiermichael antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT kiehntopfmichael antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT kamradtthomas antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT kolanossteffi antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT ankertjuliane antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT glocknerstefan antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT makarewiczoliwia antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT hagelstefan antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT bahrschristina antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT kimmigaurelia antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT proquittehans antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT guerrajoel antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT rimekdagmar antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT lofflerbettina antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT pletzmathiasw antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy AT antibodyresponseusingsixdifferentserologicalassaysinacompletelypcrtestedcommunityafteracoronavirusdisease2019outbreaktheconanstudy |